Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?

IF 33 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-10-10 DOI:10.1016/j.jhep.2025.10.004

Thierry Thévenot, Maxime Desmarets, Grégory Tio

引用次数: 0

Abstract

Section snippets

Writing assistance

Fiona Ecarnot revised the English for payment.

Authors' contributions

Drafting of the manuscript: Thevenot T and Desmarets M. Statistical analysis: Tio G, Desmarets M.

Financial support

The original study was supported by a grant from the French Ministry of Health (PHRC-16-0015, Clinical trial number: NCT03069131) and by Alfasigma laboratories (Bologna, Italy) for partial financial support

Competing Interests

The authors of this Letter declare that they do not have any conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

查看原文本刊更多论文

在严重肝硬化和腹水患者中使用利福昔明初级预防自发性细菌性腹膜炎，不是故事的终点吗？

写作帮助fiona Ecarnot修改了英语。作者的贡献手稿的起草：Thevenot T和Desmarets M.统计分析：Tio G， Desmarets M.财政支持原始研究由法国卫生部（PHRC-16-0015，临床试验号：NCT03069131）和Alfasigma实验室（博洛纳，意大利）提供部分财政支持。详情请参阅随附的ICMJE披露表格。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.